Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Diabetes Care. 2006;29(2):435-449.

Background: Glucagon-like peptide-1(7–36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility. Aims: To assess the effects of ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to results recently published in the journal Diabetes, Obesity and Metabolism.

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...